A large body of evidence accumulated over the two decades of the "interferon era" shows conclusively that HCV eradication (sustained virological response, SVR) in patients with cirrhosis reduces both liver and non-liver-related deaths.
A large body of evidence accumulated over the two decades of the "interferon era" shows conclusively that HCV eradication (sustained virological response, SVR) in patients with cirrhosis reduces both liver and non-liver-related deaths. 1, 2 When cirrhosis is subclassified according to the stage of portal hypertension, it is apparent that the benefit of SVR is higher in patients without clinically significant portal hypertension. 3 In all cohorts studied the risk of developing hepatocellular carcinoma (HCC) for patients with IFN-induced SVR, albeit reduced in comparison to those with persistent HCV infection, is not cancelled altogether. 4, 5 Hence, continuing HCC surveillance is recommended in patients with HCV cirrhosis after SVR. 5 The introduction of direct-acting antivirals (DAAs) made possible to eradicate HCV effectively at all stages of liver disease and has led to the rapid accumulation of large cohorts of patients with cirrhosis in whom treatment has been initiated regardless of the stage of the disease, including decompensated cirrhosis, in order to obtain an improvement of liver function and thus ameliorate the short and longterm outcome.
This "all-comers" approach has included patients with HCC whose tumour had been successfully treated. Also in this setting, DAAs obtain exceedingly high SVR rates thus likely prolonging the life span of these patients and creating a further period of time for HCC recur- When discussing recurrence, we should bear in mind that the estimated likelihood of HCC recurrence after its presumed cure in patients with HCV cirrhosis untreated with antivirals approximates 10% at 6 months, 20% at 12 months and 50% after 24 months since HCC treatment. • Different treatments, from palliative (transarterial chemoembolisation) to potentially curative (ablation and surgery)
• Time elapsed between presumed cure of HCC and treatment with DAAs.
In fact, some cases of cancer relapse within a few days or weeks after were younger and all had compensated cirrhosis, while those on DAAs could also have decompensated cirrhosis or signIficant comorbidity.
As a further confirmation, when the incidence of HCC during and after
DAAs is assessed after stratifyng for stage of cirrhosis, patients with
Child A cirrhosis develop HCC at a rate comparable to historical cohorts of patients treated with IFN based therapies. Indeed, two recently reported large Italian prospective cohorts 16, 17 demonstrate that the rate of occurrence of HCC in patients with Child A HCV cirrhosis and no or mild portal hypertension does not exceed 2% at 1 year of follow, while patients with Child B HCV cirrhosis have a significantly higher rate of occurrence of HCC (more than 3% despite SVR). For the latter, there is no historical benchmark of comparison, given the impossibility to treat the patients with IFN.
Further evidence supporting a positive effect of DAAs on the overall reduction in HCC comes from these cohorts 16, 17 by the finding of a higher incidence of cancer, and of all liver-related disease events, in patients who fail to obtain SVR on DAAs as compared to those with SVR.
Whether the morphological pattern of expression and the clinical behaviour of HCC in eradicated patients will be more aggressive than its usual course, as suggested by the NAVIGATORE experience, 
Key Points
• The benefit of SVR is higher in patients without clinically significant portal hypertension
• HCC occurrence in patients with compensated cirrhosis is comparable to historical controls of patients who achieved SVR after interferon-based therapy.
• Patients who achieve SVR with DAAs had a lower risk of developing liver cancer than those patients whose HCV infection was not cured.
• Data available on patients with previous HCC do not show an increased risk of HCC recurrence and report a comparable rate of reappearance of cancer among DAA-treated and untreated patients.
